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Research Brief
High and Rising      
Specialty Drug Spending
Specialty drugs—typically high-cost biologic 
medications used to treat a variety of serious, 
complex conditions ranging from cancer to 
rheumatoid arthritis to blood disorders—are 
an increasing concern for employers and 
other purchasers (see Table 1). While special-
ty drugs are prescribed for only one in every 
100 commercial health plan enrollees, these 
drugs account for an estimated 12 percent to 
16 percent of commercial prescription drug 
spending today.1 Spending on specialty drugs 
is expected to rise dramatically as drugs cur-
rently in development come to market during 
the next decade and beyond. 
Decisions about specialty drug coverage 
involve difficult trade-offs for payers and 
purchasers, according to interviews with 
representatives from health plans, benefits 
consulting firms, pharmacy consulting firms 
and other industry experts (see Data Source). 
The challenge inherent in weighing extremely 
high costs for individual patients against spe-
cialty drugs’ ability, in many cases, to extend 
lives and change the course of diseases rather 
than just treat symptoms is profound. 
Unlike conventional drugs, where spend-
ing trends have moderated for a variety of 
reasons, including patent expirations, generic 
substitution and patient incentives to use 
preferred brand-name drugs, specialty drugs 
have persistently high trends, ranging from 
14 percent to 20 percent annually in recent 
years for the three largest pharmacy benefit 
Spending on specialty drugs—typically high-cost biologic medications 
to treat complex medical conditions—is growing at a high rate and 
represents an increasing share of U.S. pharmaceutical spending and 
overall health spending. Absence of generic substitutes, or even brand-
name therapeutic equivalents in many cases, gives drug manufacturers 
near-monopoly pricing power and makes conventional tools of benefit 
design and utilization management less effective, according to a new 
qualitative study from the Center for Studying Health System Change 
(HSC). Despite the dearth of substitutes, cost pressures have prompted 
some employers to increase patient cost sharing for specialty drugs. 
Some believe this is counter-productive, since it can expose patients to 
large financial obligations and may reduce patient adherence, which 
in turn may lead to higher costs. Utilization management has focused 
on prior authorization and quantity limits, rather than step-therapy 
approaches—where lower-cost options must first be tried—that are 
prevalent with conventional drugs. Unlike conventional drugs, a sub-
stantial share of specialty drugs—typically clinician-administered 
drugs—are covered under the medical benefit rather than the phar-
macy benefit. The challenges of such coverage—high drug markups 
by physicians, less utilization data, less control for health plans and 
employers—have led to attempts to integrate medical and pharmacy 
benefits, but such efforts are still in early development. Health plans 
are experimenting with a range of innovations to control spending, but 
the most meaningful, wide-ranging innovations may not be feasible 
until substitutes, such as biosimilars, become widely available, which 
for many specialty drugs will not occur for many years.
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managers (PBMs).2 While increased utiliza-
tion and price increases both drive specialty 
drug spending, the latter typically plays a 
larger role.3 This reflects the inability of pay-
ers to exert downward pressure on price, 
given the market power of single-source 
drug manufacturers. 
No standard definition exists for specialty 
drugs. Health plans and PBMs, which often 
use or own specialty pharmacies, employ 
their own criteria, definitions and drug lists 
(see box on page 3). Most specialty drugs are 
biologic—derived from living organisms—in 
contrast to the vast majority of conventional 
drugs made from chemical compounds.5 
While specialty drugs are typically adminis-
tered by injection or infusion, they now also 
include oral and inhaled drugs. In fact, new-
generation oral drugs to treat cancer and 
multiple sclerosis, among other conditions, 
often cost far more than their injectable and 
infusible counterparts. Some of the defining 
characteristics of specialty drugs include:
•	 High	cost: The monthly spending per 
patient for a specialty drug typically 
exceeds $1,200. Commercial health plans 
and PBMs take cost into consideration in 
determining whether a drug is a specialty 
drug, though they typically do not set 
fixed-dollar cutoffs as Medicare does.6 
•	 Special	handling/administration: Drugs 
manufactured using biologic processes 
typically require special storage and han-
dling, such as refrigeration. Some specialty 
drugs must be administered by a clinician. 
•	 Complex	conditions/patient	monitor-
ing: Patients often need intensive educa-
tion and follow-up care to manage their 
specialty drug use as well as their complex 
health conditions. Dosage, adherence and 
side effects require careful monitoring to 
ensure effectiveness and patient safety. 
Specialty drugs do not fit as neatly as 
conventional drugs into traditional benefit 
structures. While self-administered specialty 
Data Source
This Research Brief draws on interviews with representatives of a variety of orga-
nizations involved in specialty drug coverage and management. Initial information 
was gathered through HSC’s 2010 Community Tracking Study site visits, which 
included 174 interviews with health plans, benefits consulting firms and other 
private-sector market experts on a variety of topics. In addition, HSC researchers 
conducted literature reviews and conducted an additional 20 in-depth interviews 
specifically on specialty drug management with more representatives from health 
plans, benefits consulting firms, pharmacy consulting firms and other industry 
experts. The additional interviews were conducted between June and September 
2011, using a semi-structured protocol and a two-person interview team. 
Interview notes were transcribed and jointly reviewed for quality and validation 
purposes. Interview responses were coded and analyzed using Atlas.ti, a qualita-
tive software tool.
Table 1 
Top Medical Conditions and Specialty Drugs, 2010
Health	Condition Per	Member	
Per	Year	
Spending
Specialty	Drug	
Examples
Average	Cost	
Per	Treated	
Member	Per	
Year
Annual	
Spending	
Trend
Inflammatory 
Conditions 
(Rheumatoid 
Arthritis, Psoriasis, 
Crohn’s Disease)
$37.16  Enbrel, Humira,   Remicade  $14,455 23.5%
Multiple Sclerosis
$29.80
Copaxone, Avonex, 
Rebif, Tysabri,  
Ampyra, Gilenya
 $24,118 25.4%
Cancer
$21.81
 Revlimid, Gleevec, 
Tarceva, Avastin, 
Provenge
 $11,089 23.7%
Blood Clots/Deep 
Vein Thrombosis $6.99
 Lovenox, Arixtra, 
Fragmin  $1,911 16.6%
Growth Deficiency $5.98 Nutropin, Genotropin  $21,144 17.8%
Pulmonary 
Hypertension $4.40 
 Tracleer, Revatio, 
Letairis  $32,570 36.3%
Respiratory 
Conditions $4.04  Xolair, Prolastin  $18,550 14.1%
Blood Cell 
Deficiency $3.89 
 Aranesp, Epogen, 
Procrit  $8,140 0.5%
Infertility $3.13  Menopur, Makena  $3,598 1.3%
Hepatitis C $2.14 Pegasys, Rebetol $12,918 0.3%
Note: Data reflect pharmacy benefit manager-adjudicated (pharmacy) claims only, meaning they do not include specialty drug 
spending covered under the medical benefit, which represents an estimated 55% of total specialty drug spending. As a result, 
the data under-represent total spending, particularly for certain conditions, such as cancer, where a majority of drug spending 
(81%) is covered under the medical benefit. 
Source: Express Scripts 2010 Drug Trend Report
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macy benefit, some employers choose 
to transfer a portion of the high costs to 
patients by adding another, higher cost-
sharing tier to the standard three-tier phar-
macy benefit design. While it is hard to 
generalize about the multitude of four-tier 
designs, the practice of transitioning from 
flat-dollar copayments in the lowest three 
tiers to coinsurance, where the patient 
pays a percentage of the total drug cost, in 
the fourth tier is quite common. A typical 
design might require a generic copayment 
of $15, a preferred brand copayment of 
$30, a nonpreferred-brand copayment of 
$60, and specialty drug coinsurance in the 
range of 10 percent to 25 percent. Within 
the fourth tier, some employers—especially 
large employers—retain a degree of finan-
cial protection for patients by applying 
out-of-pocket maximums per prescription 
fill—for example, $100 to $250—or per 
year—perhaps, $5,000. 
Tier placement of specialty drugs varies 
greatly across plans. Under some three-tier 
and four-tier designs, all specialty drugs 
are placed in the highest cost-sharing tier. 
However, other designs are more nuanced: 
Where substitutes exist, preferred specialty 
drugs might be in a lower tier. Rheumatoid 
arthritis, multiple sclerosis and growth 
deficiency are some of the conditions 
for which preferred specialty drugs have 
become increasingly available. In some 
cases, drugs achieve preferred status by 
being deemed therapeutically superior; in 
other cases, by being judged more cost-
effective. In the latter category, there is 
often a negotiation between a manufac-
turer and a health plan or PBM, with drug 
discounts or rebates granted in exchange 
for preferred tier placement. 
The prevalence of a fourth tier varies 
dramatically across health care markets. 
Four-tier designs are much less prevalent 
in markets characterized by historically 
rich benefits. For example, in Lansing and 
Health Plans, PBMs and Specialty Pharmacies
Specialty pharmacy providers are companies involved in overseeing the distribution, 
management and reimbursement of specialty drugs. The specialty pharmacy indus-
try grew out of several different market sectors but is dominated today by the PBM 
industry.4 The standalone PBMs—those unaffiliated with health plans, including giants 
Express Scripts, CVS/Caremark and Medco—have either purchased existing specialty 
pharmacies or built in-house capability. 
For fully insured products, where health plans have full latitude in determining 
specialty drug strategies, plans’ approaches toward outsourcing depend primarily on 
plan size and in-house capabilities. Some large national plans have their own specialty 
pharmacy divisions, while regional and local plans tend to contract with one or more 
specialty pharmacies—most often those owned by large standalone PBMs—to negoti-
ate prices and perform distribution and handling functions. However, utilization man-
agement is a function that plans typically keep in-house, as PBMs are seen as having 
little incentive to keep utilization in check.
For self-insured products, where employers can determine whether to carve out 
pharmacy benefits from medical benefits, employers nearly always use the same vendor 
for specialty drugs that they use for conventional drugs. That is, if conventional drug 
management is carved out to a separate PBM, specialty drug management is almost 
always included in that same carve-out; if the medical carrier (health plan) is respon-
sible for pharmacy management, that carrier has oversight over both conventional and 
specialty drugs.
drugs are almost always covered under the 
pharmacy benefit, specialty drugs admin-
istered by physicians or others in clinical 
settings—known as office-administered 
agents—typically have been covered under 
the medical benefit. Spending under the 
medical benefit is estimated to account for 
55 percent of total commercial spending 
on specialty drugs.7 The division of benefit 
structures makes management of specialty 
drugs more complex and challenging for 
payers.
This Research Brief examines three 
major approaches to specialty drug man-
agement—benefit design, pricing, and uti-
lization and care management. While some 
innovations in management hold promise, 
each approach has key limitations, largely 
because the current dearth of substitutes—
both generic and brand name—leads to 
pricing power of single-source manufactur-
ers and reduces the applicability of a range 
of key tools commonly used to control 
spending on conventional drugs.
Benefit Design Strategies
Formulary exclusions. Mainstream com-
mercial insurance products rarely exclude 
specialty drugs from their formularies. 
Once a new specialty drug receives approval 
from the Food and Drug Administration 
(FDA) and the health plan’s pharmacy and 
therapeutics (P&T) committee, its addi-
tion to the formulary is typically assured. 
P&T committee review typically focuses 
on ensuring safe and appropriate use 
and preventing off-label use, rather than 
restricting access to specialty drugs. The 
rare exceptions to this pattern of compre-
hensive formulary inclusion are found in 
the few specialty drug classes where many 
close substitutes exist—for example, growth 
hormone—and some niche insurance prod-
ucts aimed at individual and small-group 
purchasers that provide limited benefits to 
achieve much lower premiums. 
Four-tier pharmacy benefit design. For 
specialty drugs covered under the phar-
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Using patient cost-sharing 
incentives to affect drug 
choice—an effective approach 
to moderating conventional 
drug spending trends—works 
best for the few specialty drug 
classes where close substitutes 
do exist.
other Michigan communities with strong 
union presence, large employers’ pharmacy 
benefits are still transitioning from two-
tier to three-tier designs. State policy also 
can play a key role in limiting four-tier 
penetration: In 2010, New York became 
the first state to pass legislation prohibiting 
four-tier pharmacy benefit designs in fully 
insured products. In addition, four-tier 
penetration varies greatly by market seg-
ment: The smaller an employer, the greater 
the price-consciousness and likelihood of 
adopting a four-tier design. Finally, dif-
ferences among health plan and employer 
philosophies and strategies are key in 
four-tier adoption. Aetna and WellPoint 
are among the national health plans more 
actively offering four-tier designs; about 
half of their small-to-mid-sized group 
members were covered by such designs 
as of 2011. In contrast, Cigna—citing 
concerns about affordability and patient 
adherence—does not offer four-tier phar-
macy benefits in its fully insured product 
line, though it does accommodate requests 
from self-insured employers for four-tier 
designs.
Using patient cost-sharing incentives to 
affect drug choice—an effective approach 
to moderating conventional drug spending 
trends—works best for the few specialty 
drug classes where close substitutes do 
exist. The example experts often cite is 
growth hormones, where “you have six 
options and basically have great similar-
ity between agents, so [that lends itself] to 
benefit design differentiation,” according to 
a specialty pharmacy director for a national 
health plan. For most specialty drugs, how-
ever, close substitutes either do not exist 
or are few. In such cases, higher cost shar-
ing tends to transfer financial burden to 
patients without an opportunity to change 
their behavior in cost-effective ways. 
Several respondents took issue with 
markedly increasing patient cost sharing 
on philosophical grounds, noting that the 
medical conditions being treated by most 
specialty drugs are typically rare, com-
plex, expensive and beyond the control 
of patients—the very situations for which 
insurance is intended to provide financial 
protection. “These are not lifestyle drugs…
[Employers with four-tier designs] are 
almost punishing patients for having a 
disease state,” one pharmacy consultant 
observed.
Some experts also took issue with four-
tier benefit designs on practical grounds, 
arguing that higher cost sharing can be 
counterproductive by leading patients to 
stop adhering to drug regimens, which can 
in turn lead to complications requiring 
hospitalizations and other costly interven-
tions. Views were mixed as to whether 
employers end up paying more or less in 
direct medical costs under benefit designs 
requiring higher out-of-pocket costs for 
specialty drugs. That cost-benefit calcula-
tion is complex and dependent on such 
factors as employee turnover and the prev-
alence of health conditions in a particular 
employee/dependent population. Several 
experts cited the example of hepatitis C. 
There is strong evidence, they argued, 
that high out-of-pocket costs—along with 
strong drug side effects—can lead patients 
to abandon effective specialty drugs—
including a new generation of drugs that 
better target the hepatitis C virus and can 
increase the cure rate from 40 percent to 
almost 80 percent for the most common 
virus strain. Left untreated, hepatitis C ulti-
mately can result in such grave outcomes 
as liver failure. However, because these 
outcomes take many years to develop, it 
is uncertain whether the employer now 
paying for health benefits will be the same 
purchaser bearing the consequences down 
the line. 
Experts noted that adoption of four-tier 
pharmacy designs was not necessarily an 
unalterable decision for employers. One 
benefits consultant said, “A few years ago, 
we had tons of clients who did a fourth 
tier, and some rescinded it. Some went too 
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Another innovation—the integration 
of medical and pharmacy benefits—has 
garnered strong interest (see box above for 
more about integrating medical and phar-
macy benefits). In terms of benefit design, 
this approach seeks to equalize patient cost 
sharing between the medical and pharmacy 
benefits, so that patients don’t have distort-
ed incentives to use one over the other.
Pricing
Obtaining lowest unit price.	For specialty 
drugs covered under the pharmacy benefit, 
health plans take different approaches to 
obtain discounted prices from specialty 
drug manufacturers. It is common for 
smaller health plans to turn to one of the 
major PBMs—which all have acquired or 
developed their own specialty pharmacy 
divisions—to negotiate unit prices on their 
behalf, since the largest PBMs are best able 
to leverage their high volumes to obtain 
the steepest discounts from manufacturers. 
Health plans with high volumes overall—
such as the major national plans—or large 
regional market shares—such as some Blue 
Cross Blue Shield plans—often find it more 
advantageous to negotiate prices with man-
ufacturers directly rather than relying on 
a PBM. Whatever their approach to price 
negotiations, when it comes to the distri-
bution of specialty drugs to patients, most 
health plans contract with specialty phar-
macies, since these entities have expertise 
on such matters as special drug handling 
and patient education. 
Some specialty drugs are eligible for 
rebates on top of the discounted prices. 
These rebates are typically negotiated by 
whichever entity—PBM or health plan—is 
responsible for setting up the formulary 
and are paid to that entity after the drug has 
been purchased. Manufacturers are much 
more likely to offer rebates in drug classes 
where substitutes are available—for exam-
ple, rheumatoid arthritis, multiple sclerosis 
high, and they backed down.” Such rever-
sals reportedly reflect not only smaller 
savings in direct medical costs than 
expected in some cases, but also rethink-
ing by some employers of the equity of 
high out-of-pocket cost exposure for very 
sick employees.
Innovations. Some experts advocated 
the extension of value-based benefit 
design (VBBD) to include specialty drugs. 
Under this approach—the opposite of 
adding a fourth tier—patient cost barriers 
are reduced or eliminated to encourage 
adherence with treatments regarded as 
high value. Over the past decade, many 
large employers have used VBBD to 
reduce cost sharing for conventional drugs 
used to treat diabetes, hypertension and 
other common chronic conditions. While 
some large employers have shown inter-
est in extending VBBD to specialty drugs, 
the high upfront costs reportedly have 
made them reluctant to implement this 
approach. “They are taking a wait-and-see 
approach…waiting for [another employ-
er] to be the pioneer and demonstrate 
that it works…that it will save money,” 
one expert observed. Two conditions 
mentioned as affecting productivity of 
working-age people are multiple sclerosis 
and hepatitis C, so drugs controlling these 
conditions are considered prime candi-
dates for VBBD.
Another approach, income-based bene-
fit design, is designed to vary cost-sharing 
levels according to patients’ earnings. As 
one expert said, this approach “spreads 
the pain in a more equitable…[and] 
sustainable way.” This strategy has been 
implemented by a relatively small number 
of innovative employers. One engineer-
ing firm, for example, has high average 
earnings, but support and junior staff earn 
substantially less. This firm implemented 
three tiers of income-based cost sharing 
on top of its three-tiered pharmacy benefit 
design, requiring highly paid employees to 
pay a higher share out of pocket. 
Integration of Medical and Pharmacy Benefits
Currently, specialty drugs can fall under either the medical, pharmacy benefit or both 
benefits. This division can occur within a therapy class as in the case of TNF inhibi-
tors to treat rheumatoid arthritis: Remicade, an office-administered agent, typically is 
covered under the medical benefit, while self-administered agents Enbrel and Humira 
are covered under the pharmacy benefit. An example of a single drug falling under 
both the medical and pharmacy benefit is a drug that initially requires administration 
in a physician’s office, but can then be self-administered once the patient has been 
taught the technique. 
This fragmented benefit structure can mean different patient cost sharing, provider 
reimbursement, utilization management rules, clinical care management approaches 
and claims data reporting, in turn leading to misaligned incentives for patients and 
providers and lack of coordination in managing patients, among other issues. As a 
result, many payers are attempting to integrate specialty drugs under one benefit. In 
some cases, integration efforts focus on moving drugs under the medical benefit to 
the pharmacy benefit. Increasingly, however, efforts are focused on moving all spe-
cialty drugs into a separate specialty drug benefit, with the following ultimate goals, 
no matter where the drug is dispensed or administered:
•	 same patient cost sharing;
•	 same price paid for the drug;
•	 same utilization review policies and procedures;
•	 real-time integration of medical and pharmacy data; and
•	 same coordinated clinical care management activities.
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Even after discounts and 
rebates, specialty drug prices 
remain very high because, 
within most therapeutic catego-
ries, there tends to be at most 
a few drugs, which typically 
are imperfect substitutes for 
one another, and each drug is 
made by a single manufacturer.
and growth hormone deficiency. The size 
of rebates typically depends on the PBM or 
health plan’s willingness to grant the drug 
preferred-product status and place it in 
lower cost-sharing tiers.
Even after discounts and rebates, 
specialty drug prices remain very high 
because, within most therapeutic catego-
ries, there tends to be at most a few drugs, 
which typically are imperfect substitutes 
for one another, and each drug is made by 
a single manufacturer. As a result, payers 
have little, if any, ability to exert pressure on 
price. Manufacturers justify high prices by 
citing the risk and high expense of success-
fully bringing a specialty drug to market. 
Also, the rarity of many conditions treated 
by specialty drugs means that these high 
development costs have to be spread across 
a relatively small population. 
For self-insured employers seeking to 
obtain the lowest unit prices for specialty 
drugs, a key challenge is how to ensure 
that their PBMs pass through the discounts 
negotiated with manufacturers. While this 
is an issue whether the PBM is a health 
plan or a standalone PBM, experts noted 
that pass-through is a special challenge 
for employers when dealing with the larg-
est standalone PBMs. The volume of their 
businesses allows these companies to 
negotiate the steepest discounts, but they 
reportedly have the least tendency to pass 
on savings to employers. 
The contracts between employers and 
PBMs specifying specialty drug lists and 
pricing are highly complex and lack trans-
parency, and even large employers tend 
to “lack the technical sophistication to 
identify areas where [the PBM] is charg-
ing a lot more than it should,” according 
to one specialty pharmacy consultant. One 
example involves PBMs specifying broad 
discounts per drug class rather than a spe-
cific drug—an approach that allows them 
to charge the employer large markups on 
older drugs whose prices have fallen sub-
stantially over time. Another example has 
to do with contract terms for adjunctive 
therapies—which are not specialty drugs 
themselves, but need to be used in conjunc-
tion with specialty drugs. An example is a 
nausea-relieving drug used alongside many 
cancer treatment drugs. Experts noted that 
while it may be appropriate to include such 
adjunctive therapies on specialty drug lists, 
PBMs often charge an excessive markup on 
these drugs. Because of such issues, market 
observers noted that sophisticated, ongo-
ing scrutiny of employer-PBM contracts is 
needed, often by independent, specialized 
consultants who keep up to date on fast-
changing developments in specialty drugs 
and their prices.
Changing provider payment.	For spe-
cialty drugs covered under the medical 
benefit, the prevailing practice is for pro-
viders to purchase the drug, administer it 
and then bill the health plan at a markup. 
This practice, known as “buy and bill,” has 
been especially prevalent among oncolo-
gists administering cancer drugs. In large 
part to eliminate high buy-and-bill mark-
ups, plans have tried, over the past several 
years, to move office-administered specialty 
drugs from the medical benefit to the phar-
macy benefit. Under the pharmacy benefit, 
the specialty pharmacy purchases the drug, 
bills the health plan, and either dispenses it 
to the provider or to the patient who must 
bring it to the provider for administration. 
Plans making this transition have faced 
strong pushback from many providers—
notably oncologists—who depend on buy-
and-bill markups for a substantial portion 
of revenues and incomes.8 Providers often 
demand increases in payment rates for 
other services to make up for lost buy-and-
bill revenues. Providers sometimes threaten 
to leave the health plan network—a special 
concern when the provider, such as a spe-
cialty group practice, accounts for a large 
share of a particular specialty in a market. 
As a result, some plans reportedly have 
reversed decisions to move drugs out of the 
medical benefit, while others have found 
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that the switch saved them less than 
expected. 
Instead of eliminating buy-and-bill 
practices altogether, some health plans are 
keeping specialty drugs under the medical 
benefit but reducing the markup through 
different approaches. One approach is to 
require providers to purchase specialty 
drugs from the plan’s contracted specialty 
pharmacy, which has negotiated a certain 
price for the drug. A similar approach 
is to impose a fee schedule on specialty 
drugs prescribed by providers, who 
remain free to buy drugs from a supplier 
of their choice but are only reimbursed 
at a fixed price set by the plan. This fol-
lows the approach set by the Centers for 
Medicare & Medicaid Services for office-
administered drugs reimbursed under 
Medicare Part B.9 As with the elimination 
of buy-and-bill practices, these strategies 
risk triggering showdowns with provid-
ers, who may demand higher payment 
rates for other services or may consider 
abandoning the health plan’s network. 
Several regional Blue plans—whose 
dominant market shares gave them lever-
age over providers—first pioneered these 
approaches to reducing provider mark-
ups; after the ground was broken, other 
plans—including several nationals—fol-
lowed suit.
In addition, several health plans have 
introduced incentive programs to influ-
ence provider prescribing patterns. In a 
few therapeutic classes where close sub-
stitutes with very different prices exist—
for example, the taxane class of cancer 
drugs—plans are switching from the 
conventional method of paying providers 
a percentage of each drug’s cost, which 
favors prescribing the more costly drug, 
to an incentive system where providers 
receive at least as much—and sometimes 
significantly higher—payment for pre-
scribing the less-expensive drug. This 
strategy, which has been described as “a 
hybrid approach…partly pricing, partly 
UM [utilization management],” is expect-
ed to grow as substitutes become available 
in more drug classes. 
The costs borne by payers for inject-
able and infusible drugs vary substan-
tially depending on the setting where 
the drugs are administered. Some plans 
steer patients to less-costly settings, such 
as ambulatory infusion centers, often 
through the use of patient cost-sharing 
incentives. Another approach used by 
some plans involves switching patients 
from clinician-administered infusible 
drugs to self-administered injectable sub-
stitutes. However, recent technological 
advances in specialty drugs have largely 
superseded these initiatives: Oral drugs 
have been introduced over the past sev-
eral years that carry unit price tags far 
exceeding those of existing injectable and 
infusible substitutes. For example, oral 
chemotherapy drugs delivered in even the 
most-efficient setting will typically still 
cost substantially more than older infus-
ible substitutes delivered in the most-
expensive setting.  
Other innovations.	Drug pricing 
strategies used in other countries include 
direct price controls and various forms 
of value-based purchasing. Price controls 
are widely used by single-payer systems 
to determine price levels for prescription 
drugs. However, this approach is not an 
option for the U.S. commercial insurance 
market’s many payers, which have no con-
trol over market entry for drugs—given 
the unwillingness of most employers to 
restrict their formularies.
Reference pricing is one of the most 
established forms of value-based purchas-
ing strategies for pharmaceuticals. Widely 
used in several countries, reference pric-
ing is an approach where payers set a 
ceiling (reference) price within a class 
of drugs considered clinically equivalent 
and interchangeable. Consumers choos-
ing a drug with a higher price than the 
reference price are responsible for paying 
As with the elimination of 
buy-and-bill practices, these 
strategies risk triggering show-
downs with providers, who 
may demand higher payment 
rates for other services or may 
consider abandoning the 
health plan’s network.
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the entire price differential out of pocket. 
Even in countries where reference pricing 
is widely used for conventional drugs, its 
use for specialty drugs is limited by the 
dearth of therapeutic classes where true 
substitutes exist.10 As biosimilars—generic 
substitutes for biologic drugs (see box 
above for more about biosimilars)—
become available, more opportunities are 
expected to emerge for reference pricing, 
as well as tiered cost sharing and other 
approaches. However, proving therapeutic 
equivalence will be a key challenge, espe-
cially for biologic drugs, which are highly 
complex and sensitive to minor manufac-
turing variations. 
Another form of value-based purchas-
ing, outcomes-based contracting (OBC), is 
also used in some European countries with 
single-payer systems, where drug manufac-
turers accept such contracts to gain market 
entry for new drugs. OBC requires manu-
facturers to bear substantial risk—such as 
future exclusion from coverage and finan-
cial liability—based on patient outcomes. 
In the U.S. commercial market, competi-
tion among payers makes it unfeasible to 
use formulary exclusion as a tool in com-
mercial products. As a result, manufactur-
ers have little, if any, incentive to negotiate 
OBCs with commercial payers. 
A few health plans in the United States 
are experimenting with outcomes-based 
contracts. However, these contracts are 
structured very differently from the OBCs 
in Europe. Under these agreements, 
Biosimilars 
A biosimilar—also referred to as a biogeneric or a follow-on biologic—is a generic 
substitute for a previously approved biologic drug and is made by a different 
manufacturer following patent expiration of the original innovator drug. Unlike 
generic substitutes for conventional (small-molecule chemically synthesized) 
drugs, which are identical to their brand-name counterparts, the molecular com-
plexity of biologics and their sensitivity to small changes in the manufacturing 
process makes truly identical products unlikely. 
Instead of requiring interchangeability, the Biologics Price Competition and 
Innovation Act (BPCIA), signed into law in 2010, requires that biosimilars have 
no clinically meaningful differences in safety, purity and potency from the original 
innovator drug. This law grants 12-year exclusivity to the drug manufacturer of 
the innovator product. Separately, each innovator drug is protected by a patent, 
whose protection period typically exceeds the market exclusivity period by at least 
a few years. BPCIA’s market exclusivity provision grants a minimum period of 
protection to the innovator drug in the event that a patent is proven invalid.11  
The Food and Drug Administration is still in the process of establishing an 
approval pathway for biosimilars. Many believe the FDA regulations will be mod-
eled on criteria used by the European Union, which has approved 13 biologics 
since establishing its pathway in 2005. Although the FDA approval pathway still 
has to be finalized, clinical research on biosimilars is already underway.
There are a few examples of biosimilars already available in the United States. 
These are limited to simple biologics, such as insulin and growth hormone, whose 
substitutes were granted an abbreviated approval pathway by the Drug Price 
Competition and Patent Term Restoration Act of 1984, commonly known as the 
Hatch-Waxman Act, the same legislation that established a system for generic ver-
sions of conventional drugs.
the discounts are tied to the plans’ ability to 
demonstrate their members’ drug regimen 
adherence and reductions in relapses. This 
approach, then, appears to be more of an 
extension of the volume discounts granted 
by drug manufacturers to gain market share, 
rather than a true OBC approach of putting 
the manufacturer at financial risk based on 
evidence of drug effectiveness. 
Finally, some countries, such as the United 
Kingdom, are experimenting with a particular 
form of value-based purchasing called “value-
based pricing,” which uses comparative-effec-
tiveness research (CER) data to vary price 
controls for manufacturers and cost-sharing 
levels for patients. As with other value-based 
purchasing strategies, the applicability of 
this tool for specialty drugs is limited by the 
dearth of substitutes. In addition, it requires 
CER data, which is not mandated in the U.S. 
drug regulatory approval process. As a result, 
manufacturers have no incentive to provide 
such evidence. In addition, the price-control 
aspect of this strategy is not available to U.S. 
commercial payers, as noted previously.
In summary, some value-based purchas-
ing approaches have potential to become 
useful cost-containment tools for specialty 
drugs, but that potential depends largely on 
the development of more close substitutes in 
each therapeutic class—particular less-costly 
biosimilars.
Utilization and Care 
Management
Utilization management. Specialty drugs cov-
ered under the pharmacy benefit are subject to 
more pervasive and stringent utilization man-
agement (UM) than those under the medical 
benefit. Prior authorization, for example, is 
widely practiced—“nearly universal,” accord-
ing to one respondent—under the phar-
macy benefit but far less prevalent under the 
medical benefit, where retrospective review 
remains more common. One benefits consul-
tant estimated that specialty drugs under the 
medical benefit are subject to prior authoriza-
tion only about 5 percent of the time. 
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A major reason is that most contracts 
between health plans and providers con-
tain no provisions for prior authoriza-
tion or other UM protocols for specialty 
drugs under the medical benefit. Health 
plans are concerned that pushing to add a 
prior-authorization provision will result in 
provider resistance and perhaps provider 
exit from health plan networks. As with 
provider payment methods discussed 
previously, respondents suggested that 
implementing prior authorization under 
the medical benefit appears to be easier 
for regional Blue Cross Blue Shield plans 
whose large market shares give them 
leverage over providers. 
Information technology poses another 
key barrier to prior authorization. 
WellPoint is one of the plans that has an 
Internet portal allowing providers to sub-
mit and receive authorization for specialty 
drug orders in real time. For the many 
plans that lack this real-time data capabil-
ity, however, the use of prior authoriza-
tion would entail more administrative 
expenses and also might delay physicians’ 
ability to implement or change drug regi-
mens—a serious issue when dealing with 
extremely sick patients with complex con-
ditions who often need on-the-spot medi-
cation adjustments during office visits.       
The types of UM tools employed for 
specialty drugs tend to differ from those 
used for conventional drugs. Step therapy, 
where lower-cost options must be tried 
first, is commonly applied to conventional 
drugs but plays much less of a role for 
specialty drugs, because of the dearth of 
substitutes and the lack of CER evidence. 
However, quantity limits—often in the 
form of 15-day or 30-day supply limits—
are nearly universal for specialty drugs 
under the pharmacy benefit, because of 
the need to ensure dosage safety and to 
minimize waste of expensive drugs in case 
drug regimens need to be changed—a fre-
quent occurrence with specialty drugs.
Over the past several years, there has 
been increasing interest in extending 
the full range of UM tools already in use 
under the pharmacy benefit to drugs 
covered under the medical benefit. This 
is part of a larger effort to integrate medi-
cal and pharmacy benefits for specialty 
drugs. However, efforts to impose more 
UM on drugs under the medical ben-
efit have been hampered by important 
limitations, including the lack of detailed, 
reliable claims information about office-
administered drugs under the medical 
benefit. 
Each drug billed under the phar-
macy benefit is identified by a National 
Drug Code (NDC), which specifies the 
drug name, manufacturer, dosage form, 
strength and package size. In contrast, 
drugs billed under medical claims are 
identified using far less specific Health 
Care Procedure Coding System (HCPCS) 
codes, which are unique only to a drug’s 
chemical name, but not to its manufac-
turer, dosage strength or package size. 
And, unlike the NDC number, which 
becomes available when the drug receives 
FDA approval and before it enters the 
market, HCPCS codes are not defined 
until six to 18 months after the drug has 
been launched. Drugs administered in 
the interim under the medical benefit are 
billed to a general “unclassified” code. 
As a result, the HCPCS system does not 
allow payers to track and manage utiliza-
tion the same way they can under the 
pharmacy benefit.12 In response, some 
health plans are rewriting provider con-
tracts to require NDCs on medical claims. 
However, this approach has met with 
some provider resistance and has been 
hampered by the inability of some claims 
and billing systems to accommodate the 
11-digit NDCs.
Even if all specialty drugs billed under 
medical claims can be converted to the 
NDC system, integration of medical and 
pharmacy utilization data poses serious 
challenges. These challenges tend to be 
For the many plans that lack this 
real-time data capability, howev-
er, the use of prior authorization 
would entail more administrative 
expenses and also might delay 
physicians’ ability to implement 
or change drug regimens—a 
serious issue when dealing with 
extremely sick patients with com-
plex conditions who often need 
on-the-spot medication adjust-
ments during office visits.
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especially acute when the pharmacy and 
medical benefits are managed by two dif-
ferent entities, with a health plan (medical 
carrier) managing medical benefits and a 
separate PBM overseeing pharmacy ben-
efits. Contracts with self-insured employers 
often require the medical carrier and PBM 
to share data with each other, but even 
when both entities cooperate, experts noted 
that data lags of at least two weeks are more 
the norm than real-time data sharing.
Experts generally viewed health plans—
even when just acting as medical carriers 
on behalf of self-insured employers—as 
more aggressive in managing specialty drug 
utilization than standalone PBMs. The lat-
ter were widely perceived as having little 
incentive to keep utilization of high-cost 
drugs in check. As one benefits consultant 
observed, PBMs “earn a margin on each 
prescription filled…that’s the core of their 
business, so you wouldn’t expect them to 
scrutinize [utilization] too carefully.”
Care management. Experts viewed 
strong clinical care management as critical 
to promoting both good health outcomes 
and cost containment. Key challenges 
include very sick patients with complex 
chronic conditions requiring complicated 
drug regimens, the need to adjust drugs or 
fine-tune dosage, and strong side effects 
leading patients to abandon drug regimens. 
Experts cited cancer and hepatitis C as 
examples where medications caused such 
unpleasant, sustained side effects that keep-
ing patients compliant over time was partic-
ularly difficult. Several respondents empha-
sized the importance of a “high-touch” 
approach to care management, where staff 
not only has clinical expertise but also the 
ability to “form personal connections with 
patients” and motivate them to adhere to 
demanding drug regimens. 
As is the case for utilization manage-
ment, the lack of integration between medi-
cal and pharmacy benefits creates barriers 
to effective and coordinated care manage-
ment. For specialty drugs covered under 
the medical benefit, a patient’s physician 
is responsible for major care management 
activities, including patient education, dos-
age monitoring and managing side effects, 
but other care management aspects are like-
ly to fall under case management or disease 
management programs overseen by a health 
plan or a separate vendor. Coordination 
among these entities is typically far from 
optimal, and “some [care management] 
services are duplicated…[while] others fall 
through the cracks,” according to one health 
plan executive. Even for specialty drugs 
covered only under the pharmacy benefit, 
coordination of care management activities 
still poses challenges. For example, the spe-
cialty pharmacy handles patient education, 
dosage monitoring, side-effect tracking, and 
coordination with the patient’s physician 
about drug regimens, while the health plan 
or PBM is responsible for other aspects of 
care management related to the patient’s 
medical condition. 
Unlike utilization management, PBMs 
were seen by most respondents as having 
an edge over health plans in key aspects 
of care management, such as overseeing 
and tweaking complicated drug regimens 
and conducting outreach to physicians and 
patients. However, several experts cautioned 
that the effectiveness of any single PBM in 
performing care management fluctuated 
substantially across the many health condi-
tions that specialty drugs are used to treat. 
Innovations. Many respondents noted 
that the introduction of biosimilars—still 
many years away—will make it possible to 
apply step therapy more broadly as part of 
specialty drug management. However, sev-
eral experts noted that step therapy will be 
less straightforward for specialty drugs than 
conventional drugs, because therapeutic 
equivalence across drugs will be difficult to 
determine, and small differences in biotech-
nology manufacturing processes can lead 
to important differences in how patients 
respond to treatments. 
A promising innovation already under-
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Experts generally viewed health 
plans—even when just acting 
as medical carriers on behalf 
of self-insured employers—as 
more aggressive in managing 
specialty drug utilization than 
standalone pharmacy benefits 
managers.
way involves health plans working with phy-
sician specialty societies and other provider 
organizations to establish clinical pathways, 
which include drug regimens and other care 
protocols, for particular disease states. For 
example, several large national plans and 
regional Blue plans have implemented clini-
cal pathway programs for different kinds of 
cancer. Instead of imposing UM protocols 
on providers in a top-down approach, this 
is a more collaborative approach. Blue Cross 
Blue Shield of Michigan is among the plans 
to reward provider groups that successfully 
adopt clinical pathways, through its pay-
for-performance Physician Group Incentive 
Program.
Another innovation involves the use 
of smaller, specialized specialty pharma-
cies that have expertise in specific, com-
plex disease states. However, the ability 
of employers to use these niche specialty 
pharmacies is constrained by their exist-
ing contracts with the PBMs managing 
the employers’ pharmacy benefits. In 
most contracts, the PBM either prohibits 
disease-specific carve-outs outright or 
increases its own pricing if the employer 
opts for disease-specific carve-outs. As 
a result, respondents noted that the only 
employers currently able to use these niche 
specialty pharmacies appear to be hospital 
systems, which are not dependent on large 
PBMs to negotiate drug discounts because 
they are able to obtain favorable so-called 
“class of trade” drug pricing directly from 
manufacturers. 
Key Takeaways
Among the common themes that emerged 
from interviews with industry experts, the 
following stand out:
Key drug management strategies that 
have proven effective for conventional 
drugs often are less applicable to specialty 
drugs: The lack of close substitutes for most 
specialty drugs greatly reduces, or elimi-
nates altogether, the ability of tools like 
cost-sharing tiers and step therapy to steer 
patients and providers to cost-effective 
alternatives. It also sharply limits incentives 
for drug manufacturers to offer substantial 
price concessions. In contrast, other tools, 
such as prior authorization and quantity 
limits—which can help curb unnecessary 
or inappropriate use, improve patient safety, 
and reduce waste—are emphasized more in 
the management of specialty drugs.
Biosimilars are expected to lead to key 
breakthroughs in specialty drug manage-
ment, but their impact won’t be seen for 
many years: The introduction of generic 
substitutes should allow payers to broaden 
the use of preferred drug tiers and step 
therapy, thereby exerting downward 
pressure on prices. However, achieving 
therapeutic equivalence—for biosimilar 
manufacturers—and assessing therapeutic 
equivalence—for regulators—are likely to 
be difficult, given the complex nature of 
biologics. Also, the expensive manufactur-
ing process means that biosimilars may not 
yield savings as sizable as those achieved 
by conventional generic drugs. And, it will 
be an uncertain number of years before 
biosimilars can make an impact on com-
petition and cost, because (1) innovator 
products are granted 12 years of market 
exclusivity and often are protected by pat-
ents lasting years beyond that; and (2) the 
FDA approval process—which has yet to be 
finalized—is expected to be rigorous and 
lengthy.  
 Integration of medical and pharmacy 
benefits is a goal worth pursuing, but how 
to achieve it isn’t clear: Efforts to overhaul 
the currently fragmented benefit struc-
ture—which can misalign incentives for 
patients and providers and result in unco-
ordinated patient management—are in the 
early stages of development, and results 
are uneven at best. Equalizing patient cost 
sharing for specialty drugs regardless of 
whether they are covered under the phar-
macy or medical benefit is probably the 
most straightforward dimension of integra-
tion. Other aspects of integration present 
tougher challenges. The ability to track 
utilization and spending under the medical 
benefit remains limited, which in turn hin-
ders the ability to manage a large segment 
of specialty drug utilization. Real-time 
integration of utilization data remains ham-
pered by limitations in claims and billing 
systems. Also, as office-administered drugs 
are moved out of the medical benefit’s buy-
and-bill approach, health plans will have to 
deal with fallout from physicians who see 
both their margins and clinical autonomy 
eroding. 
Patient adherence is critical to good 
health outcomes: As one pharmacy consul-
tant observed, “Price tags and performance 
guarantees [from PBMs] are one thing, 
but if you [can’t achieve] compliance, it’s 
all a waste.” Both financial factors—high 
out-of-pocket costs—and nonfinancial fac-
tors—strong side effects—pose formidable 
barriers to patient adherence and positive 
health outcomes. A combination of non-
punitive cost sharing and strong care man-
agement may reduce these barriers. One 
benefit design approach that can help make 
financial burden more manageable is an 
income-based cost-sharing structure. 
Employers should ensure that their 
specialty drug strategies are aligned with 
their overall benefits and business strate-
gies: Decisions on specialty drug coverage 
require tough trade-offs between cost and 
access. Which cost-access combination an 
employer chooses will be heavily influenced 
by competitive conditions in the industry 
and the geographic and labor markets 
where an employer operates. Short-term 
cost containment can have unintended 
consequences—for example, increased 
cost sharing leading to reduced adherence 
to drug regimen, in turn leading to high-
cost complications. Such negative impacts 
come more into play for employers with 
low worker turnover and those still offering 
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comprehensive retiree health benefits, as 
these are the employers likely to be paying 
the bill in the long term for patients cur-
rently taking specialty drugs. Cost-benefit 
comparisons of different drug coverage 
options will be more accurate if they are 
able to account for impact on employee 
productivity—which is hard to measure—
as well as direct medical costs. 
PBMs’ interests may not align with 
employers’ interests: Some employers may 
be relying heavily on their PBMs to set 
specialty drug policies, determine specialty 
drug lists, and pass through discounts 
from manufacturers, without indepen-
dently verifying whether their own needs 
are best served in these arrangements. 
Employers need to recognize that PBMs’ 
interests can diverge sharply from their 
own interests, as PBMs don’t have the 
same incentives as employers to limit the 
volume and the prices of drugs. Because 
the specialty drug sector is complex and 
the vast majority of employers lack the 
in-house expertise to deal with PBMs on 
an equal footing, many employers likely 
would benefit from having independent 
experts assess their PBM contract terms 
and audit compliance with those terms.
Policy Implications
Spending on specialty drugs is expected to 
skyrocket over the next decade and beyond, 
as some of the hundreds of biologics cur-
rently in the pipeline gain approval and hit 
the market. The number of conditions that 
can be treated with specialty drugs—and 
thus the number of patients eligible for 
treatment with these high-cost drugs—are 
both expected to soar. These developments 
will intensify the cost and access trade-offs 
that payers and purchasers already face.
People who enroll in coverage through 
health insurance exchanges beginning in 
2014 will find access to specialty drugs 
varying substantially across states, depend-
ing on the decisions that each state makes 
regarding benchmarks for essential health 
benefits. If a state chooses the Federal 
Employees Health Benefits plan as the 
benchmark, this plan’s open formulary 
will ensure that enrollees have coverage 
for all FDA-approved drugs; in contrast, 
state benchmarking to small-group prod-
ucts will result in less comprehensive drug 
coverage.13 Another important question 
for specialty drug users will be their out-
of-pocket exposure. The guidance recently 
released by the Department of Health and 
Human Services on actuarial value leaves 
insurers a great deal of latitude on how to 
specify cost-sharing levels for particular 
services; thus, exchange products with the 
same actuarial value may differ markedly 
in cost sharing for prescription drugs. 
What already seems clear is that specialty 
drug users will be among the population 
of sick enrollees who are most likely to 
choose plans with the most generous cov-
erage—the platinum and gold plans, with 
90 percent and 80 percent actuarial values, 
respectively. As the sickest enrollees sort 
themselves into the most generous plans, 
it could generate a so-called death spiral, 
where premiums for those plans may 
increase unsustainably over time.
Payers are looking to biosimilars to 
provide some relief from soaring specialty 
drug costs in the future. However, that 
relief may take many years to arrive, as 
federal law grants original brand-name 
biologics 12 years of market exclusivity, and 
many biologics are protected by patents 
for years after exclusivity expires. Some 
observers and stakeholders, including the 
Federal Trade Commission, believe that a 
period significantly shorter than 12 years 
would be sufficient to promote innovation; 
the Obama administration has proposed 
shortening the exclusivity period to seven 
years.14 It may be useful for policy makers 
to revisit this issue, balancing the need to 
promote drug innovation against the prior-
ity of making relatively affordable substi-
tutes available in a timely manner. 
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Spending on specialty drugs 
is expected to skyrocket over 
the next decade and beyond, 
as some of the hundreds of 
biologics currently in the pipe-
line gain approval and hit the 
market.
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